13 results on '"Scortechini, A. R."'
Number of results to display per page
Search Results
2. P698: BOSUTINIB DOSE OPTIMIZATION IN THE SECOND-LINE TREATMENT OF ELDERLY CML PATIENTS: EXTENDED 3-YEAR FOLLOW-UP AND FINAL RESULTS OF THE BEST STUDY
- Author
-
Castagnetti, F., primary, Bocchia, M., additional, Abruzzese, E., additional, Capodanno, I., additional, Bonifacio, M., additional, Rege Cambrin, G., additional, Crugnola, M., additional, Binotto, G., additional, Elena, C., additional, Lucchesi, A., additional, Bergamaschi, M., additional, Albano, F., additional, Luciano, L., additional, Sorà, F., additional, Lunghi, F., additional, Stagno, F., additional, Cerrano, M., additional, Iurlo, A., additional, Scortechini, A. R., additional, Leonetti Crescenzi, S., additional, Spadano, R., additional, Trabacchi, E., additional, Lunghi, M., additional, Spinosa, G., additional, Ferrero, D., additional, Rapezzi, D., additional, Ladetto, M., additional, Nocilli, L., additional, Gugliotta, G., additional, Iezza, M., additional, Cavo, M., additional, Saglio, G., additional, Pane, F., additional, and Rosti, G., additional
- Published
- 2022
- Full Text
- View/download PDF
3. P712: ASCIMINIB ITALIAN MANAGED ACCESS PROGRAM: EFFICACY PROFILE IN HEAVILY PRE-TREATED CML PATIENTS
- Author
-
Breccia, M., primary, Russo Rossi, A. V., additional, Martino, B., additional, Abruzzese, E., additional, Annunziata, M., additional, Binotto, G., additional, Ermacora, A., additional, Fava, C., additional, Giaccone, L., additional, Giai, V., additional, Nardozza, A. P., additional, Coco, P., additional, Gozzini, A., additional, Levato, L., additional, Lucchesi, A., additional, Luciano, L., additional, Maria Cristina, M., additional, Rege-Cambrin, G., additional, Santoro, M., additional, Scappini, B., additional, Scortechini, A. R., additional, Sportoletti, P., additional, Trabacchi, E., additional, and Castagnetti, F., additional
- Published
- 2022
- Full Text
- View/download PDF
4. D-dimer and reduced dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study
- Author
-
Palareti, G., Poli, D., Pesavento, R., Legnani, C., Antonucci, E., Bucherini, E., Testa, S., Paoletti, O., Chistolini, A., Ceccato, D., Martinelli, I., Bucciarelli, P., Falanga, A., Tosetto, A., Sarti, L., Mastroiacovo, D., Cosmi, B., Visona, A., Santoro, R. C., Zanatta, N., Grandone, E., Bertu, L., Pengo, V., Caiano, L., Prandoni, P., Lotti, E., Crudele, F., Ageno, W., Abenante, A., Colombo, G., Guarascio, M., Cancellieri, E., Morandini, R., Zambelli, S., Martini, S., Vastola, M., Serrao, A., Abbattista, M., Artoni, A., Capecchi, M., Gianniello, F., Scimeca, B., Barcella, L., Gamba, S., Lerede, T., Maggioni, A., Schieppati, F., Russo, L., Zunino, F., Artuso, A., Bellesso, S., Cadau, J., Carli, G., Nichele, I., Perbellini, O., Caronna, A., Gabrielli, F., Lami, F., Nicolini, A., Scaglioni, F., Pinelli, M., Desideri, G., Borgese, L., Favaretto, E., Libra, A., Migliaccio, L., Sartori, M., Panzavolta, C., Scandiuzzi, T., Zalunardo, B. -M., Ierardi, A., Leotta, M., Strangio, A., Guzzon, S., Colaizzo, D., Favuzzi, G., Lombardi, M. R., Ferrini, P. M., Tassoni, M. I., Corradini, S., Iotti, M., Lambertini, I., Veropalumbo, M. R., Lessiani, G., Parisi, R., Bortoluzzi, C., H. N., Vo, Chiarugi, P., Casini, M., Violo, C., Nuti, M., Angeloni, L., Carrozzi, L., Pancani, R., Chimera, D., Conti, V., Meschi, C., Cattaneo, M., Podda, G., Birocchi, S., Cuppini, S., Marzolo, M., Milan, M., Martini, G., Merelli, S., Pontoglio, S., Portesi, N., Villalta, S., De Lucchi, L., Sponghiado, A., Becattini, C., Giustozzi, M., Vinci, A., Pignatelli, P., Bucci, T., Menichelli, D., Pastori, D., Pomero, F., Casalis, S., Galli, E., Ciammaichella, M., Maida, R., De Cristofaro, R., Alberelli, M. A., Basso, M. R., De Candia, E., Di Gennaro, L., Mumoli, N., Capra, R., Orlando, M., Porta, C., Rotiroti, G., Demarco, M., Petrillo, P., Rossi, E., Bartolomei, F., Soldati, D., Russo, U., Burgo, I., Ziliotti, M., Pataccini, C., Terroni, L., Ugolotti, M. C., Di Giorgio, A., Cavagna, L., Mete, F., Gino, M., Santoro, A., De Carlo, A., Cappelli, R., Bicchi, M., Dyrmo, L., Grifoni, E., Masotti, L., Ria, L., Spagnolo, M., Rupoli, S., Federici, I., Morsia, E., Scortechini, A. R., Torre, E., Franchini, M., Montorsi, P., Galgano, G., De Luca, A., Muiesan, M. L., Paini, A., Stassaldi, D., Denas, G., and Palareti G, Poli D, Ageno W, Legnani C, Antonucci E, Bucherini E, Testa S, Paoletti O, Chistolini A, Serrao A, Martinelli I, Bucciarelli P, Falanga A, Tosetto A, Sarti L, Mastroiacovo D, Cosmi B, Visonà A, Santoro RC, Zanatta N, Grandone E, Bertù L, Pengo V, Caiano LM, Prandoni P
- Subjects
venous thromboembolism, d-dimer, anticoagulation therapy, apixaban ,anticoagulation therapy ,Recurrence ,Settore MED/09 - MEDICINA INTERNA ,D-dimer, venous thromboembolism, oral anticoagulants ,apixaban ,Humans ,Anticoagulants ,Hematology ,Prospective Studies ,Venous Thromboembolism ,d-dimer - Abstract
D-dimer assay is used to stratify patients with unprovoked venous thromboembolism (VTE) for the risk of recurrence. However, this approach was never evaluated since direct oral anticoagulants are available. With this multicenter, prospective cohort study, we aimed to assess the value of an algorithm incorporating serial D-dimer testing and administration of reduced-dose apixaban (2.5 mg twice daily) only to patients with a positive test. A total of 732 outpatients aged 18 to 74 years, anticoagulated for ≥12 months after a first unprovoked VTE, were included. Patients underwent D-dimer testing with commercial assays and preestablished cutoffs. If the baseline D-dimer during anticoagulation was negative, anticoagulation was stopped and testing repeated after 15, 30, and 60 days. Patients with serially negative results (286 [39.1%]) were left without anticoagulation. At the first positive result, the remaining 446 patients (60.9%) were given apixaban for 18 months. All patients underwent follow-up planned for 18 months. The study was interrupted after a planned interim analysis for the high rate of primary outcomes (7.3%; 95% confidence interval [CI], 4.5-11.2), including symptomatic proximal deep vein thrombosis (DVT) or pulmonary embolism (PE) recurrence, death for VTE, and major bleeding occurring in patients off anticoagulation vs that in those receiving apixaban (1.1%; 95% CI, 0.4-2.6; adjusted hazard ratio [HR], 8.2; 95% CI, 3.2-25.3). In conclusion, in patients anticoagulated for ≥1 year after a first unprovoked VTE, the decision to further extend anticoagulation should not be based on D-dimer testing. The results confirmed the high efficacy and safety of reduced-dose apixaban against recurrences. This trial was registered at www.clinicaltrials.gov as #NCT03678506.
- Published
- 2022
5. MOBILIZATION-DRIVEN POST-CONSOLIDATION THERAPY IN 72 ELDERLY AML PATIENTS: FEASIBILITY AND EFFICACY OF ASCT VS LOW DOSE GEMTUZUMAB-OZOGAMICIN: PH-O131
- Author
-
Olivieri, A., Capelli, D., Chiarucci, M., Poloni, A., Saraceni, F., Mancini, G., Trappolini, S., Montanari, M., Scortechini, I., Rupoli, S., Offidani, M., Scortechini, A. R., Gini, G., Discepoli, G., and Leoni, P.
- Published
- 2014
6. Coexistence of two discordant B-cell lymphomas in the skin and lymph node: report of a case with primary cutaneous follicle-center lymphoma and nodal mantle-cell lymphoma
- Author
-
GOTERI, G., RUPOLI, S., STRAMAZZOTTI, D., DISCEPOLI, G., SCORTECHINI, A. R., GIACCHETTI, A., MORICHETTI, D., TASSETTI, A., PULINI, S., MULATTIERI, S., STRONATI, A., and LEONI, P.
- Published
- 2007
7. Bleeding Risk in Very Old Patients on Vitamin K Antagonist Treatment
- Author
-
Polimanti, David, Antonucci, Eva, Testa, S., Tosetto, A., Ageno, W., Palareti, G., Collaborators: Poli, Italian Federation Of Anticoagulation C. l. i. n. i. c. s., Paoletti, O., Nante, G., Pengo, V., Carini, U., Guazzaloca, G., Scortechini, A. R., Canafoglia, L., Tomassetti, S., Restifo, D., Ciampa, A., Pignatelli, Pasquale, Basili, Stefania, Saliola, M., Di Gennaro, L., De Cristofaro, R., Caprioli, M., Pedrini, S., Orlandini, F., Benedetti, R., Ruocco, L., Tiraferri, E., Cappelli, R., Piana, A., Armani, U., Porcu, A., Falco, P., Da Col, P., Marongiu, F., Barcellona, D., Falanga, A., Lerede, T., Galbo, L., Bucherini, E., Insana, A., Grasso, M. V., Masciocco, L., and Pini, F.
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Vitamin K ,medicine.drug_class ,venous thromboembolism ,Hemorrhage ,elderly ,atrial fibrillation ,hemorrhage ,warfarin ,Age Distribution ,Aged, 80 and over ,Anticoagulants ,Atrial Fibrillation ,Cooperative Behavior ,Female ,Humans ,Incidence ,Italy ,Proportional Hazards Models ,Prospective Studies ,Risk Factors ,Stroke ,Venous Thromboembolism ,Physiology (medical) ,Cardiology and Cardiovascular Medicine ,oral anticoagulation ,80 and over ,medicine ,Medical prescription ,Prospective cohort study ,Aged ,Proportional hazards model ,business.industry ,Incidence (epidemiology) ,Warfarin ,Atrial fibrillation ,Vitamin K antagonist ,medicine.disease ,Surgery ,business ,medicine.drug - Abstract
Background— Vitamin K antagonist (VKA) therapy is increasingly being used for the prevention of venous thromboembolism and stroke in atrial fibrillation. Bleeds are the major concern for VKA prescription, especially in very old patients who carry many risk factors for bleeding. We performed a large multicenter prospective observational study that enrolled very old patients to evaluate the quality of anticoagulation and the incidence of bleedings. Methods and Results— The study included 4093 patients ≥80 years of age who were naïve to VKA for thromboprophylaxis of atrial fibrillation or after venous thromboembolism. Patients' demographic and clinical data were collected, and the quality of anticoagulation and the incidence of bleeding were recorded. The follow-up was 9603 patient-years; median age at the beginning of follow-up was 84 years (range, 80 to 102 years). We recorded 179 major bleedings (rate, 1.87 per 100 patient-years), 26 fatal (rate, 0.27 per 100 patient-years). The rate of bleeding was higher in men compared with women (relative risk, 1.4; 95% confidence interval, 1.12 to 1.72; P =0.002) and among patients ≥85 years of age compared with younger patients (relative risk, 1.3; 95% confidence interval, 1.0 to 1.65; P =0.048). Time in therapeutic range was 62% (interquartile range, 49% to 75%). History of bleeding, active cancer, and history of falls were independently associated with bleeding risk in Cox regression analysis. Conclusion— In this large study on very old patients on VKA carefully monitored by anticoagulation clinics, the rate of bleedings was low, suggesting that age in itself should not be considered a contraindication to treatment. Adequate management of VKA therapy in specifically trained center allows very old and frail patients to benefit from VKA thromboprophylaxis.
- Published
- 2011
8. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
- Author
-
Castagnetti, F, Gugliotta, G., Breccia, M., Stagno, F., Iurlo, A., Albano, F., Abruzzese, E., Martino, B., Levato, L., Intermesoli, T., Pregno, P., Rossi, G., Gherlinzoni, F., Leoni, P., Cavazzini, F., Venturi, C., Soverini, S., Testoni, N., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Baccarani, M., on behalf of the GIMEMA CML Working Party (Lucarelli, G., Polimeno, G., Ladetto, M., Pini, M., Rupoli, S., Scortechini, A. R., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Specchia, G., Russo, Rossi., Rambaldi, A., Ferrari, M. L., Palandri, F., Luatti, S., Iacobucci, I., Bochicchio, M. T., Apolinari, M., Fogli, M., Cervello, I., Capucci, A., Giuliani, G., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Molica, S., Lentini, M., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cuneo, A., Ciccone, M., Bosi, A., Gozzini, A., Gobbi, M., Pierri, I., Chianese, R., De Blasio, A., Ciccone, F., Capochiani, E., Pelosini, M., Musolino, C., Russo, S., Cortelezzi, A., Luppi, M., Marasca, R., Pogliani, E. M., Gambacorti-Passerini, C., Luciano, L., Izzo, B., Ferrara, F., Annunziata, M., Mettivier, V., Sessa, U., Latte, G., Noli, D., Rege-Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidor, I., Di Bartolomeo, P., Di Lorenzo, R., Vallisa, D., Trabacch, I., Pizzuti, M., Zuffa, E., Salvucci, M., Ronco, F., Lelo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Sica, S., Sorà, F., Latagliata, R., De Fabritiis, P., Trawiska, M., Amadori, S., Cantonetti, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Mengarelli, A., Romano, A., Tafuri, A., Montefusc, O., Iuliano, F., Infusino, S., Dore, F., Fozza, C., Bocchia, M., Defina, M., Liberati, Am., Luzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Nicolosi, M., Gottardi, M., Calistri, E., Fanin, R., Tiribelli, M., Pizzolo, G., Bonifacio, M., Rodeghiero, F., Di Bona, E. )., Castagnetti, F, Gugliotta, G., Breccia, M., Stagno, F., Iurlo, A., Albano, F., Abruzzese, E., Martino, B., Levato, L., Intermesoli, T., Pregno, P., Rossi, G., Gherlinzoni, F., Leoni, P., Cavazzini, F., Venturi, C., Soverini, S., Testoni, N., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Baccarani, M., and on behalf of the GIMEMA CML Working Party [, Palandri F.], Pane, Fabrizio, Gugliotta, G, Breccia, M, Stagno, F, Iurlo, A, Albano, F, Abruzzese, E, Martino, B, Levato, L, Intermesoli, T, Pregno, P, Rossi, G, Gherlinzoni, F, Leoni, P, Cavazzini, F, Venturi, C, Soverini, S, Testoni, N, Alimena, G, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Rosti, G, Baccarani, M, and GAMBACORTI PASSERINI, C
- Subjects
DIAGNOSED CHRONIC-PHASE ,Oncology ,Male ,Cancer Research ,Time Factors ,bcr-abl ,Fusion Proteins, bcr-abl ,Antineoplastic Agent ,Hematology ,Anesthesiology and Pain Medicine ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,80 and over ,Cumulative incidence ,Young adult ,Chronic ,Aged, 80 and over ,Leukemia ,PATIENTS RECEIVING IMATINIB ,CHRONIC MYELOGENOUS LEUKEMIA ,TYROSINE KINASE INHIBITORS ,BCR-ABL1 TRANSCRIPT LEVELS ,EARLY MOLECULAR RESPONSE ,CML WORKING PARTY ,3-YEAR FOLLOW-UP ,EUROPEAN LEUKEMIANET ,400 MG ,Myeloid leukemia ,Middle Aged ,Prognosis ,Treatment Outcome ,Retreatment ,Imatinib Mesylate ,Female ,Tyrosine kinase ,Human ,medicine.drug ,Adult ,medicine.medical_specialty ,Time Factor ,Adolescent ,Prognosi ,Protein Kinase Inhibitor ,Socio-culturale ,Antineoplastic Agents ,Treatment results ,Follow-Up Studie ,Young Adult ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,Internal medicine ,medicine ,Humans ,Protein Kinase Inhibitors ,Aged ,Antineoplastic Combined Chemotherapy Protocol ,business.industry ,Fusion Proteins ,Imatinib ,Follow-Up Studies ,Surgery ,Imatinib mesylate ,BCR-ABL Positive ,business ,Myelogenous - Abstract
For almost 10 years imatinib has been the therapeutic standard of chronic myeloid leukemia. The introduction of other tyrosine kinase inhibitors (TKIs) raised a debate on treatment optimization. The debate is still heated: some studies have protocol restrictions or limited follow-up; in other studies, some relevant data are missing. The aim of this report is to provide a comprehensive, long-term, intention-to-treat, analysis of 559 newly diagnosed, chronic-phase, patients treated frontline with imatinib. With a minimum follow-up of 66 months, 65% of patients were still on imatinib, 19% were on alternative treatment, 12% died and 4% were lost to follow-up. The prognostic value of BCR-ABL1 ratio at 3 months (⩽10% in 81% of patients) was confirmed. The prognostic value of complete cytogenetic response and major molecular response at 1 year was confirmed. The 6-year overall survival was 89%, but as 50% of deaths occurred in remission, the 6-year cumulative incidence of leukemia-related death was 5%. The long-term outcome of first-line imatinib was excellent, also because of second-line treatment with other TKIs, but all responses and outcomes were inferior in high-risk patients, suggesting that to optimize treatment results, a specific risk-adapted treatment is needed for such patients.
- Published
- 2015
9. The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study
- Author
-
Poli, D., Antonucci, E., Testa, S., Cosmi, B., Palareti, G., Ageno, W., Italian Federation Of Anticoagulation Clinics Poli, Fcsa D., Paoletti, O., Nante, G., Pengo, V., Carini, U., Guazzaloca, G., Scortechini, A. R., Canafoglia, L., Tomassetti, S., Restifo, D., Desio Vimercate, A. O., Ciampa, A., Pignatelli, Pasquale, Basili, Stefania, Saliola, Mirella, Di Gennaro, L., De Cristofaro, R., Caprioli, M., Pedrini, S., Orlandini, F., Benedetti, R., Ruocco, L., Tiraferri, E., Cappelli, R., Piana, A., Armani, U., Porcu, A., Falco, P., Da Col, P., Marongiu, F., Barcellona, D., Falanga, A., Lerede, T., Galbo, L., Bucherini, E., Insana, A., Masciocco, L., Pini, F., D. Poli, E. Antonucci, S. Testa, B. Cosmi, G. Palareti, W. Ageno, Poli, D, Antonucci, E, Testa, S, Cosmi, B, Palareti, G, Ageno, W, Paoletti, O, Nante, G, Pengo, V, Carini, U, Guazzaloca, G, Scortechini, A, Canafoglia, L, Tomassetti, S, Restifo, D, Ciampa, A, Pignatelli, P, Basili, S, Saliola, M, Di Gennaro, L, De Cristofaro, R, Caprioli, M, Pedrini, S, Orlandini, F, Benedetti, R, Ruocco, L, Tiraferri, E, Cappelli, R, Piana, A, Armani, U, Porcu, A, Falco, P, Dal Col, P, Marongiu, F, Barcellona, D, Falanga, A, Lerede, T, Galbo, L, Bucherini, E, Insana, A, Masciocco, L, and Pini, F
- Subjects
bleeding, bleeding scores, elderly venous thromboembolism, vitamin K, antagonist ,Predictive validity ,Bleeding ,Bleeding scores ,Elderly ,Venous thromboembolism ,Vitamin K antagonist ,medicine.medical_specialty ,vitamin K antagonist ,medicine.drug_class ,Internal medicine ,Atrial Fibrillation ,Medicine ,Prospective cohort study ,Old patients ,business.industry ,Proportional hazards model ,Risk Factor ,Mortality rate ,Hematology ,Surgery ,bleeding score ,bleeding ,bleeding scores ,elderly ,venous thromboembolism ,vitamin k antagonist ,Risk stratification ,business - Abstract
BACKGROUND: The optimal duration of anticoagulant treatment after venous thromboembolism (VTE) should be evaluated in relation to bleeding risk. This assessment is particularly difficult with elderly patients, because of their increased risk of both recurrences and hemorrhages. Bleeding risk stratification models have been proposed, but their predictive ability in very elderly patients is unknown. We aimed to assess six bleeding stratification models in this setting, by using information available in our dataset. PATIENTS AND METHODS: Patients aged >/= 80 years receiving vitamin K antagonists (VKAs) for the secondary prevention of VTE were eligible for this prospective cohort study. All patients were followed at Italian anticoagulation clinics for monitoring of VKA treatment. Risk factors for bleeding were collected, and major bleeding events and mortality were documented during follow-up. The association of bleeding events with the available risk factors was tested by means of Cox regression analysis; the c-statistic was used to quantify the predictive validity of the classification schemes. RESULTS: A total of 1078 patients (37.2% males; mean age, 84 years) were enrolled in the study, for a total observation period of 1981 patient-years. The rate of major bleeding was 2.4 per 100 patient-years (47 events; one was fatal). The mortality rate was 5.2 per 100 patient-years. None of the considered risk factors were significantly associated with bleeding events. The predictive validity of the risk stratification models was low, and the most accurate model was not specifically developed for VTE patients (HEMORR2 HAGES, c-statistic 0.60, 95% confidence interval 0.49-0.70). CONCLUSIONS: Bleeding risk stratification models appear to have little accuracy in very elderly VTE patients.
- Published
- 2013
10. Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas
- Author
-
Pulini, S., primary, Rupoli, S., additional, Goteri, G., additional, Pimpinelli, N., additional, Alterini, R., additional, Tassetti, A., additional, Scortechini, A. R., additional, Offidani, M., additional, Mulattieri, S., additional, Stronati, A., additional, Brandozzi, G., additional, Giacchetti, A., additional, Mozzicafreddo, G., additional, Ricotti, G., additional, Filosa, G., additional, Bettacchi, A., additional, Simonacci, M., additional, Novelli, N., additional, and Leoni, P., additional
- Published
- 2007
- Full Text
- View/download PDF
11. Expression of c-myb and B-myb oncogenes on myelofibrotic marrow fibroblasts.
- Author
-
Scortechini AR, Rupoli S, Piccinini G, Luchetti MM, Cantori I, Gabrielli A, and Leoni P
- Subjects
- Aged, Bone Marrow metabolism, Cell Division, Cells, Cultured, DNA-Binding Proteins biosynthesis, Female, Fibroblasts metabolism, Fibroblasts pathology, Humans, Kinetics, Liver pathology, Male, Middle Aged, Oncogene Proteins genetics, Primary Myelofibrosis genetics, Proto-Oncogene Proteins biosynthesis, Proto-Oncogene Proteins c-myb, Spleen pathology, Trans-Activators biosynthesis, Bone Marrow pathology, Cell Cycle Proteins, DNA-Binding Proteins genetics, Primary Myelofibrosis metabolism, Primary Myelofibrosis pathology, Proto-Oncogene Proteins genetics, Trans-Activators genetics
- Abstract
The term IMF (Idiopathic Myelofibrosis) refers to a primary bone marrow disease in which the normal haematopoietic bone marrow cells are for unknown reasons replaced by connective tissue. The pathogenesis of the disease has not been clarified yet. We have speculated that the increment of proliferation of bone marrow fibroblasts in IMF may be the consequence of the over-expression of some oncogenes, leading or contributing to the fibrosis via a cell amplification. Thus, we investigated the possible role of the c-myb and B-myb genes in IMF and control bone marrow fibroblasts in different culture conditions to evaluate proliferation parameters in the absence or presence of serum. Using the reverse transcriptase polymerase chain reaction technique, we demonstrated that the kinetics of induction was similar for both c-myb and B-myb during the proliferation of normal bone marrow fibroblasts. When compared to normal controls, cultured IMF fibroblasts showed more elevated values of c-myb and B-myb RNA; furthermore, after a 72 hours stimulation with serum, c-myb and B-myb messages remained relatively high in myelofibrotic fibroblasts. Finally, after serum starvation, c-myb and to a lesser extent B-myb RNA levels remained unusually high in IMF fibroblasts, while under the same experimental conditions c-myb and B-myb messages became virtually undetectable in normal bone marrow fibroblasts. To our knowledge this work represents the first description of an abnormal behavior of these genes in IMF fibroblasts.
- Published
- 1999
- Full Text
- View/download PDF
12. [Biologic aspects and clinical use of granulocyte growth factor].
- Author
-
Rupoli S, Battelli N, Del Prete S, Salvi A, Cinciripini A, Scortechini AR, Cantori I, Barulli S, and Leoni P
- Subjects
- Humans, Granulocyte Colony-Stimulating Factor physiology, Granulocyte Colony-Stimulating Factor therapeutic use
- Abstract
Granulocyte colony stimulating factors (G-CSF) has a wide spectrum of action: it stimulates proliferation and differentiation of granulocyte-macrophage progenitors, it promotes the chemotactic activity of monocytes and granulocytes and it develops the antibody-dependent cytotoxicity of neutrophils. In vivo G-CSF induces leucocytosis and it hastens the granulocyte recovery after chemio-radiotherapy. So it has been used in many pathologies: aplastic anaemia, AIDS in treatment with antiviral drugs, myelodysplastic syndromes, acute leukemias and solid tumors. If G-CSF is administered after chemotherapy, both in acute leukemias and in solid tumors, it reduces the duration of neutropenia and the number of febrile episodes so that it is possible to give the whole therapy at the planned dosage with no delay. However G-CSF does not modify the incidence of complete remissions and the overall survival. G-CSF allowed the increase of dose-intensity in chemoresistent neoplasms even if this therapy is always complicated by a heavy extrahaematological toxicity. Moreover G-CSF shortens the total duration of neutropenia after autologous or allogenic bone marrow and peripheral stem cell transplantation even if the appearance of the first neutrophil is not accelerated.
- Published
- 1995
13. [Idiopathic myelofibrosis. Main pathogenetic, prognostic and therapeutic aspects].
- Author
-
Barulli S, Rupoli S, Cinciripini A, Scortechini AR, Cantori I, and Leoni P
- Subjects
- Age Factors, Child, Female, Humans, Male, Middle Aged, Prognosis, Primary Myelofibrosis diagnosis, Primary Myelofibrosis etiology
- Abstract
Primary myelofibrosis is a complex disorder characterized by bone marrow fibrosis with no apparent cause. It is known in literature under a wide number of terms, reflecting the variety of clinical features and the different pathogenetic hypotheses. In most cases it is plain that marrow fibrosis is secondary to a clonal myeloproliferative disorder and, in particular, to the presence of abnormal megakaryocytes secreting (MKDGF/PDGF); but probably some other growth factors synthesized by megakaryocytes and contained in platelet alpha-granules are involved. The molecular event that determines the advantage of the clonal growth is, at present, unknown, and the pathogenetic importance of some chromosome anomalies is still under discussion. Over the last years, besides megakaryocyte dysplasia, several fibrogenetic mechanisms such as a bone marrow immune damage have been taken into consideration. Studies on prognostic factors regarding the main clinical, hematological and histological parameters have given conflicting results, because of low incidence of the disease, different criteria used for the diagnosis, and different terms of the clinic presentation of the pathology. Although a great deal of progress has been made in terms of pathogenetic mechanisms, a lot of questions must be still definitively settled, further in depth studies still have to go into many matters.
- Published
- 1995
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.